ICU

SeaStar Medical Holding Corporation · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website eastarmedical.com
Employees(FY) 9
ISIN US81256L2034

Performance

+45.22%

+14.0%

-30.06%

-72.69%

+17.53%

YTD

-88.63%

Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.

Advanced Technical Analysis

Technical Analysis of ICU 2025-02-03

The stock exhibits a generally bullish sentiment, with a strong Moving Average Score of 70 indicating positive momentum, while the Technical Score of 67 further supports this outlook. However, the Oscillators Score of 53 suggests a more neutral stance, indicating potential caution in the short term despite the overall bullish trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ICU

Stock Rank

Recent News & Updates

2024-08-08 00:38
SeaStar Medical Holding Corporation Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 6, 2024 to Discuss Your Rights ICU(Globenewswire)
2024-07-25 21:00
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE Therapy at Cincinnati Children's(Globenewswire)
2024-07-22 20:30
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's FDA-Approved QUELIMMUNE Therapeutic Device(Globenewswire)
2024-07-16 21:00
Nuwellis Marks First Commercial Sale of QUELIMMUNE Therapy to Cincinnati Children's(Globenewswire)
2024-07-15 20:30
CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical's Selective Cytopheretic Device Pivotal Trial(Globenewswire)
2024-07-11 20:30
SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner(Globenewswire)
2024-07-11 04:05
SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-07-09 21:00
SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-07-02 20:30
SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device(Globenewswire)
2024-06-11 19:00
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now(Globenewswire)
2024-06-10 20:30
SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology(Globenewswire)
2024-06-10 19:00
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now(Globenewswire)
2024-06-09 20:30
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company(Globenewswire)
2024-06-06 20:30
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation(Globenewswire)
2024-06-06 04:05
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024(Globenewswire)
2024-06-05 20:30
SeaStar Medical Announces 25-for-1 Reverse Stock Split(Globenewswire)
2024-05-21 20:30
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant Eligibility(Globenewswire)
2024-05-19 22:53
ICU Stock Earnings: SeaStar Medical Holding Misses EPS for Q1 2024(Investorplace)
2024-05-14 04:05
SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-04-29 20:30
SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure(Globenewswire)
2024-04-17 04:00
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update(Globenewswire)
2024-04-16 11:52
ICU Stock Earnings: SeaStar Medical Holding Misses EPS for Q4 2023(Investorplace)
2024-04-10 20:30
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference(Globenewswire)
2024-04-01 23:26
LM Funding America, Inc. (NASDAQ:LMFA) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-26 20:30
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17(Globenewswire)
2024-03-11 20:30
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients(Globenewswire)
2024-03-11 04:05
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024(Globenewswire)
2024-02-26 19:30
Manuscript Discussing the Benefit of SeaStar Medical's Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure(Globenewswire)
2024-02-21 18:58
Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune(Globenewswire)
2024-02-21 18:53
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney Injury(Globenewswire)

Page 2 of 4

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.